Literature DB >> 8142652

Multiple cis-acting elements in the human immunodeficiency virus type 2 enhancer mediate the response to T-cell receptor stimulation by antigen in a T-cell hybridoma line.

M C Hannibal1, D M Markovitz, G J Nabel.   

Abstract

Transcription directed by the human immunodeficiency virus type 2 long terminal repeat (HIV-2 LTR) responds to T-cell antigen receptor signaling. Agents that stimulate T-cell signaling pathways activated by the antigen receptor, such as phorbol ester, plant lectin, or anti-CD3 antibody treatment, have been shown to increase transcription directed by the HIV-2 LTR. In this study, we examine the activation of the HIV-2 LTR in T cells stimulated with the physiologic ligand of the T-cell receptor, antigenic peptide presented by a major histocompatibility molecule. HIV-2 reporter plasmids were transfected into the antigen-specific T-cell hybridoma, 2B4.11, where they responded to antigen-dependent activation. This antigen-mediated transcriptional activation of the HIV-2 enhancer required the presence of at least four regulatory elements in the HIV-2 enhancer, including two purine boxes, PuB1 and PuB2, an AP-1/CREB-like element (pets), and kappa B. This finding suggests that signals emanating from the antigen receptor act coordinately on a set of transcription factors that bind to conserved HIV-2 regulatory elements. Despite differences in the organization of potentially related enhancer elements in HIV-2 and IL-2, these enhancers exploit a similar signal transduction pathway to induce gene expression in antigen-activated T cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8142652

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  The sequence and structure of the 3' arm of the first stem-loop of the human immunodeficiency virus type 2 trans-activation responsive region mediate Tat-2 transactivation.

Authors:  C Browning; J M Hilfinger; S Rainier; V Lin; S Hedderwick; M Smith; D M Markovitz
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

2.  Physical interactions between Ets and NF-kappaB/NFAT proteins play an important role in their cooperative activation of the human immunodeficiency virus enhancer in T cells.

Authors:  A G Bassuk; R T Anandappa; J M Leiden
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

3.  DEK, an autoantigen involved in a chromosomal translocation in acute myelogenous leukemia, binds to the HIV-2 enhancer.

Authors:  G K Fu; G Grosveld; D M Markovitz
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

4.  Human immunodeficiency virus type 2 produces a defect in CD3-gamma gene transcripts similar to that observed for human immunodeficiency virus type 1.

Authors:  I Segura; C Delmelle-Wibaut; M Janssens; Y Cleuter; A van den Broeke; R Kettmann; K E Willard-Gallo
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

5.  GLI-2 modulates retroviral gene expression.

Authors:  M J Smith; S D Gitlin; C M Browning; B R Lane; N M Clark; N Shah; S Rainier; D M Markovitz
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

6.  Solution NMR structure of the C-terminal domain of the human protein DEK.

Authors:  Matthew Devany; N Prasad Kotharu; Hiroshi Matsuo
Journal:  Protein Sci       Date:  2004-07-06       Impact factor: 6.725

7.  The peri-kappa B site mediates human immunodeficiency virus type 2 enhancer activation in monocytes but not in T cells.

Authors:  N M Clark; M C Hannibal; D M Markovitz
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

8.  Insight into HIV-2 latency may disclose strategies for a cure for HIV-1 infection.

Authors:  Suha Saleh; Lenard Vranckx; Rik Gijsbers; Frauke Christ; Zeger Debyser
Journal:  J Virus Erad       Date:  2017-01-01

9.  DEK binding to class II MHC Y-box sequences is gene- and allele-specific.

Authors:  Barbara S Adams; Hyuk C Cha; Joanne Cleary; Tan Haiying; Hongling Wang; Kajal Sitwala; David M Markovitz
Journal:  Arthritis Res Ther       Date:  2003-05-23       Impact factor: 5.156

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.